Silverback Therapeutics, Inc. (SBTX)

NASDAQ: SBTX · IEX Real-Time Price · USD
4.93
+0.27 (5.79%)
At close: Sep 26, 2022 4:00 PM
5.14
+0.21 (4.26%)
Pre-market: Sep 26, 2022 5:47 PM EDT
5.79%
Market Cap 174.89M
Revenue (ttm) n/a
Net Income (ttm) -90.18M
Shares Out 35.47M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,708
Open 4.56
Previous Close 4.66
Day's Range 4.56 - 4.96
52-Week Range 2.80 - 11.85
Beta n/a
Analysts Sell
Price Target 5.10 (+3.4%)
Earnings Date Nov 8, 2022

About SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. [Read more...]

Industry Biotechnology
IPO Date Dec 4, 2020
Employees 90
Stock Exchange NASDAQ
Ticker Symbol SBTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SBTX stock is "Sell." The 12-month stock price forecast is 5.1, which is an increase of 3.45% from the latest price.

Price Target
$5.1
(3.45% upside)
Analyst Consensus: Sell
Stock Forecasts

News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: RFPTMXVIVO
1 day ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: HNGRIEAZY
1 month ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: IEAPBFXRMO
1 month ago - PRNewsWire

SILVERBACK THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS , Aug. 10, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

1 month ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RFP

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of...

Other symbols: IEAPBFXRFP
1 month ago - PRNewsWire

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX

NEW YORK , July 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rate...

1 month ago - PRNewsWire

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Silverback Thera...

2 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.

NEW YORK , July 22, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. ("Silverbac...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Silverback Therapeutics, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - July 22, 2022) - Rigrodsky Law, P.A. is investigating Silverback Therapeutics, Inc. ("Silverback") (NASDAQ: SBTX) regarding possible breaches of fiduciary duties ...

2 months ago - Newsfile Corp

SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Sh...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Silverback Therapeutics, Inc. (NASDAQ: SBTX) and ARS Pharmaceuticals, Inc. is fair to Sil...

2 months ago - Business Wire

Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative

Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San-Diego based ARS P...

2 months ago - GeekWire

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE & SAN DIEGO--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive ...

2 months ago - Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

4 months ago - Business Wire

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

4 months ago - Business Wire

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continu...

5 months ago - Benzinga

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.

5 months ago - GeekWire

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

5 months ago - Business Wire

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

7 months ago - Business Wire

Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

7 months ago - Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

8 months ago - Business Wire

SBTX Final Deadline - Bronstein, Gewirtz & Grossman, LLC Reminds Silverback Therapeutics, Inc. Investors of Class Act...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Silverback Therapeutics, Inc. ("Silverback" or t...

8 months ago - Business Wire

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Silverback Therapeutics, Inc. Investors to Secure Counsel...

New York, New York--(Newsfile Corp. - January 4, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1)...

8 months ago - Newsfile Corp

DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Laws...

NEW YORK, Jan. 3, 2022 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons and entities that purchased or otherwise acquired: (a) Silverback Therapeutics, I...

8 months ago - PRNewsWire

Deadline Tomorrow Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therap...

Los Angeles, California--(Newsfile Corp. - January 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Silverback Therap...

8 months ago - Newsfile Corp

SBTX DEADLINE TOMORROW: ROSEN, A TOP RANKED FIRM, Encourages Silverback Therapeutics, Inc. Investors to Secure Counse...

New York, New York--(Newsfile Corp. - January 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1)...

8 months ago - Newsfile Corp